학술논문

DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.
Document Type
article
Source
Journal of diabetes and its complications. 36(2)
Subject
Cardiovascular System
Humans
Cardiovascular Diseases
Diabetes Mellitus
Type 2
Hypoglycemic Agents
Renal Insufficiency
Chronic
Atherosclerotic cardiovascular disease
Chronic kidney disease
Clinical practice
Consensus recommendations
Heart failure
Type 2 diabetes
Kidney Disease
Diabetes
Clinical Trials and Supportive Activities
Clinical Research
Hepatitis
Heart Disease
Chronic Liver Disease and Cirrhosis
Liver Disease
Cardiovascular
Digestive Diseases
Prevention
Management of diseases and conditions
7.1 Individual care needs
7.3 Management and decision making
Metabolic and endocrine
Good Health and Well Being
Clinical Sciences
Endocrinology & Metabolism
Language
Abstract
Type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), and heart failure (HF)-along with their associated risk factors-have overlapping etiologies, and two or more of these conditions frequently occur in the same patient. Many recent cardiovascular outcome trials (CVOTs) have demonstrated the benefits of agents originally developed to control T2D, ASCVD, or CKD risk factors, and these agents have transcended their primary indications to confer benefits across a range of conditions. This evolution in CVOT evidence calls for practice recommendations that are not constrained by a single discipline to help clinicians manage patients with complex conditions involving diabetes, cardiorenal, and/or metabolic (DCRM) diseases. The ultimate goal for these recommendations is to be comprehensive yet succinct and easy to follow by the nonexpert-whether a specialist or a primary care clinician. To meet this need, we formed a volunteer task force comprising leading cardiologists, nephrologists, endocrinologists, and primary care physicians to develop the DCRM Practice Recommendations, a multispecialty consensus on the comprehensive management of the patient with complicated metabolic disease. The task force recommendations are based on strong evidence and incorporate practical guidance that is clinically relevant and simple to implement, with the aim of improving outcomes in patients with DCRM. The recommendations are presented as 18 separate graphics covering lifestyle therapy, patient self-management education, technology for DCRM management, prediabetes, cognitive dysfunction, vaccinations, clinical tests, lipids, hypertension, anticoagulation and antiplatelet therapy, antihyperglycemic therapy, hypoglycemia, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), ASCVD, HF, CKD, and comorbid HF and CKD, as well as a graphical summary of medications used for DCRM.